Empagliflozin + Placebo + Sitagliptin + Placebo
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Jan 1, 2015 → Feb 1, 2017
NCT ID
NCT01984606About Empagliflozin + Placebo + Sitagliptin + Placebo
Empagliflozin + Placebo + Sitagliptin + Placebo is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01984606. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01984606 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Diabetes Mellitus, Type 2